![](/img/cover-not-exists.png)
Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results)
Vermersch, Patrick, Erälinna, Juha-Pekka, Nicholas, Richard, Oreja-Guevara, Celia, Siva, Aksel, Van Wijmeersch, Bart, Wiendl, Heinz, Buffels, Regine, Kuhelj, Robert, Wei, WeiVolume:
37
Journal:
Multiple Sclerosis and Related Disorders
DOI:
10.1016/j.msard.2019.11.063
Date:
January, 2020
File:
PDF, 102 KB
2020